Paclitaxel is used as a first-line and subsequent therapy for the treatment of various cancers. However, the function and mechanisms of action of paclitaxel in non-small-cell lung cancer (NSCLC) remain unknown. In this study, the molecular mechanism underlying the anticancer activity of paclitaxel was investigated in vitro in a human NSCLC cell line carrying the EGFR exon 19 deletion (PC9).

中文翻译：

---

紫杉醇通过活性氧介导的 DNA 损伤和 EGFR/PI3K/AKT/mTOR 信号通路抑制来阻碍 EGFR 突变的 PC9 细胞生长。

紫杉醇用作治疗各种癌症的一线和后续疗法。然而，紫杉醇在非小细胞肺癌（NSCLC）中的功能和作用机制尚不清楚。在这项研究中，在携带 EGFR 外显子 19 缺失 (PC9) 的人 NSCLC 细胞系中，体外研究了紫杉醇抗癌活性的分子机制。